• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-临床研究 • 上一篇    下一篇

人尿激肽原酶对高危非致残性缺血性脑血管病的临床疗效分析

张远   

  1. 西峡县中医院
  • 收稿日期:2017-08-03 修回日期:2017-08-03 出版日期:2017-08-25 发布日期:2017-08-25

Clinical efficacy of human urinary kallidinogenase in high-risk non-disabling ischemic cerebrovascular diseases patients

zhangyuan   

  1. Xixia County TCM Hospital
  • Received:2017-08-03 Revised:2017-08-03 Online:2017-08-25 Published:2017-08-25

摘要: 目的:探讨人尿激肽原酶对高危非致残性缺血性脑血管病的临床疗效。方法:选择将2016年1月至2017年1月我院接受治疗的高危非致残性缺血性脑血管的患者100例,随机分为观察组和对照组,各50例,对照组采用阿司匹林、氯吡格雷抗血小板治疗,观察组在对照组基础上采用人尿激肽原酶治疗,分析两组患者新发缺血性卒中的发生率以及治疗前后凝血功能变化。结果:观察组患者新发缺血性卒中等的发生率显著低于对照组,P<0.05,观察组治疗前后的凝血酶原时间(PT)、纤维蛋白原(Fib)与活化部分凝血活酶时间(APTT)与对照组无显著差异,P>0.05,观察组在静滴人尿激肽原酶前后的舒张压与收缩压无显著差异,P>0.05。结论:对高危非致残性缺血性脑血管病患者在应用阿司匹林、氯吡格雷抗血小板治疗的基础上联用人尿激肽原酶治疗,能降低患者出现新发缺血性脑卒中的发病概率,不会影响患者的凝血功能与血压。

Abstract: Objective: To analyze the clinical effect of human urinary kallidinogenase in HR-NICE (high-risk non-disabling ischemic cerebrovascular events) patients. Method: 100 HR-NICE patients treated from January 2016 to January 2017 in our hospital were selected. The subjects were randomly divided into two groups, 50 cases each group. The control group took the double-antibody therapy, namely the double antiplatelet therapy of Aspirin and Clopidogrel. On the basis, the observation group also took the human urinary kallidinogenase. The incidence rate of emerging ischemic stroke and coagulation function for two groups were analyzed. Result: The incidence rate of emerging ischemic stroke for observation group was significantly lower than control group (P<0.05);before and after treatment, the index of PT, Fib and APTT for two groups was not significantly different (P>0.05);before and after the intravenous drip of human urinary kallidinogenase, the diastolic blood pressure and systolic blood pressure for observation group was not significantly different (P>0.05).Conclusion: For HR-NICE patients, the combined therapy of the double antiplatelet therapy of Aspirin and Clopidogrel with human urinary kallidinogenase can reduce the incidence rate of emerging ischemic strok. In addition, the coagulation function and blood pressure is not affected. It is worthy of clinical promotion and application.